CURE was on site at the 2025 ASH Annual Meeting, sharing expert conversations and patient-focused reporting that highlighted progress in blood cancer care. The 2025 American Society of Hematology ...

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this ...

Academic-community partnerships can reduce patient travel burdens while maintaining high-quality cancer care, as demonstrated by successful high-dose cytarabine consolidation delivery. A flow ...

The meeting will highlight bispecific antibodies and "off the shelf" CAR T-cell therapies, potentially transforming treatment paradigms. Fixed-duration therapies are gaining attention for their ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. The updated ...

Geron Corporation (NASDAQ:GERN) is one of the best long-term penny stocks to invest in. Geron Corporation (NASDAQ:GERN) announced on December 8 that new data was presented at the 67th American Society ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies ...

New Tapestri® assay measures both genotypic and transcriptional signals within individual cells, enabling researchers to map resistance, relapse, and lineage evolution across hematologic malignancies.

New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement -- Strong activity observed across ESA-refractory and ESA-intolerant patients, and across ...

Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...

New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDS Additional poster ...